Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
Add more filters










Publication year range
1.
Biomed Chromatogr ; 35(11): e5205, 2021 Nov.
Article in English | MEDLINE | ID: mdl-34192355

ABSTRACT

Dabrafenib is a novel small molecule tyrosine kinase inhibitor (TKI) which is used to treat metastatic melanoma. The aim of this research was to survey the effects of dabrafenib on human UDP-glucuronosyltransferases (UGTs) and to evaluate the risk of drug-drug interactions (DDIs). The formation rates for 4-methylumbelliferone (4-MU) glucuronide and trifluoperazine-glucuronide in 12 recombinant human UGT isoforms with or without dabrafenib were measured and HPLC was used to investigate the inhibitory effects of dabrafenib on UGTs. Inhibition kinetic studies were also conducted. In vitro-in vivo extrapolation approaches were further used to predict the risk of DDI potentials of dabrafenib via inhibition of UGTs. Our data indicated that dabrafenib had a broad inhibitory effect on 4-MU glucuronidation by inhibiting the activities of UGTs, especially on UGT1A1, UGT1A7, UGT1A8, and UGT1A9, and dabrafenib could increase the area under the curve of co-administered drugs. Dabrafenib is a strong inhibitor of several UGTs and the co-administration of dabrafenib with drugs primarily metabolized by UGT1A1, 1A7, 1A8 or 1A9 may induce potential DDIs.


Subject(s)
Glucuronosyltransferase/antagonists & inhibitors , Imidazoles/pharmacology , Oximes/pharmacology , Protein Kinase Inhibitors/pharmacology , Chromatography, High Pressure Liquid , Drug Interactions , Glucuronosyltransferase/chemistry , Glucuronosyltransferase/genetics , Glucuronosyltransferase/metabolism , Humans , Hymecromone/analysis , Hymecromone/metabolism , Kinetics , Protein Isoforms , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Triflupromazine/analysis , Triflupromazine/metabolism
2.
Chem Pharm Bull (Tokyo) ; 53(1): 147-50, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15635254

ABSTRACT

To assess the affinity of psychotropic phenothiazine drugs, triflupromazine (TFZ) and chlorpromazine (CPZ), for the membranes of central nervous system and the other organs in the body, the partition coefficients (Kps) of these drugs to phosphatidylcholine (PC)-phosphatidylserine (PS) and PC-phosphatidylethanolamine (PE) small and large unilamellar vesicles (SUV, LUV) were examined by a second-derivative spectrophotometric method, since PS is abundantly contained in the membranes of the central nervous system and PE is distributed widely in the membranes of the organs in the body. Size and preparation methods of the vesicles did not affect the Kp values at each aminophospholipid content suggesting that the partition of the phenothiazine drugs was not affected by the structural differences in the vesicles such as their curvature or asymmetric distribution of the phospholipids between the outer and inner layers of the bilayer membranes. However, the Kp values of both drugs increased remarkably according to the PS content in the bilayer membranes, i.e., the Kp values for the vesicles of 30 mol% PS content were about 3 times of that for the vesicles of PC alone, while both Kp values slightly reduced with the increase in the content of PE in the bilayer membranes of PC-PE vesicles. The results indicate that both drugs have higher affinity for the PC-PS bilayer membranes than for the PC and PC-PE membranes, which can offer an evidence for the fact that TFZ and CPZ are predominantly distributed and accumulated in the brain and nerve cell membranes that contain PS abundantly.


Subject(s)
Chlorpromazine/analysis , Glycerophospholipids/analysis , Lipid Bilayers/analysis , Triflupromazine/analysis , Chlorpromazine/chemistry , Glycerophospholipids/chemistry , Lipid Bilayers/chemistry , Phosphatidylcholines/analysis , Phosphatidylcholines/chemistry , Phosphatidylethanolamines/analysis , Phosphatidylethanolamines/chemistry , Phosphatidylserines/analysis , Phosphatidylserines/chemistry , Spectrophotometry/methods , Triflupromazine/chemistry , Water/analysis , Water/chemistry
3.
Dtsch Tierarztl Wochenschr ; 103(4): 125-7, 1996 Apr.
Article in English | MEDLINE | ID: mdl-8925772

ABSTRACT

The azaphenothiazine neuroleptic prothipendyl (Dominal) is suspected to be administered illegally at low doses to race-horses to improve their performance. Since for this species pharmacokinetic data of the drug are missing we studied its elimination from blood and urine in a standard-bred mare. At a low (subtherapeutic) dose (i.v., 0.24 mg/kg) the horse is described to be less excited while locomotor activity and attention remain unaffected. In contrast, sedation and ataxia are brought about at 1 mg/kg (therapeutic dose). Identification of prothipendyl given i.v. at subtherapeutic doses was achieved in blood only by means of gas chromatography-mass spectrometry (GC-MS), while the neuroleptic was found both in blood and urine upon 1 mg/kg. Quantification of the neuroleptic was carried out by virtue of triflupromazine as internal standard with the MS operating in the selected ion monitoring (SIM) mode. Under these conditions, the detection limit was 10 ng/ml body fluid. Disappearance of prothipendyl from blood was determined in the horse studied from terminal elimination process, yielding a t1/2 of 2.4 h. The results suggest that for detection of prothipendyl in the horse--in contrast to phenothiazine neuroleptics--screening of blood is preferred over urine as the drug was not recovered in urine after administration of subtherapeutic doses.


Subject(s)
Antipsychotic Agents/analysis , Doping in Sports , Horses/metabolism , Thiazines/analysis , Animals , Antipsychotic Agents/pharmacokinetics , Antipsychotic Agents/pharmacology , Behavior, Animal/drug effects , Female , Gas Chromatography-Mass Spectrometry/veterinary , Horses/physiology , Reference Standards , Thiazines/pharmacokinetics , Thiazines/pharmacology , Triflupromazine/analysis
4.
Biol Cell ; 74(1): 99-103, 1992.
Article in English | MEDLINE | ID: mdl-1511253

ABSTRACT

The intracellular localization of two neurotropic drugs, flunitrazepam (benzodiazepine) and triflupromazine (phenothiazine), was studied by secondary ion mass spectrometry microscopy (SIMS) in three varieties of cells. The images of the intracellular distributions of the two drugs are easily obtained by selecting the fluorine atom of the molecules. These images show that the drug from the benzodiazepine group is mainly located in the nuclei, whereas the phenothiazine is exclusively located inside the cytoplasm.


Subject(s)
Central Nervous System/chemistry , Flunitrazepam/analysis , Mass Spectrometry/methods , Microscopy/methods , Triflupromazine/analysis , Animals , Animals, Newborn , Cells, Cultured , Mice
8.
J Chromatogr ; 120(1): 65-80, 1976 May 12.
Article in English | MEDLINE | ID: mdl-5460

ABSTRACT

A reversed-phase thin-layer chromatographic method has been developed for the determination of partition coefficients. A support phase has been chosen, following investigation of the lack of adsorptive properties, which has a minimal effect on the pH of the buffer system. A stationary phase has been chosen to give deltaRm values of the same magnitude as Hansch pi values for a series of phenothiazines. The method can be applied to molecules of a wide range of lipophilicity following preliminary investigations of suitable phase-volume ratios and of the pH and composition of the binary mobile phase, providing adsorption on the support phase is excluded.


Subject(s)
Chromatography, Thin Layer/methods , Phenothiazines/analysis , Adsorption , Chlorpromazine/analysis , Hydrogen-Ion Concentration , Lipids , Promazine/analogs & derivatives , Promazine/analysis , Triflupromazine/analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...